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Abstract
High levels of arsenic exposure have been associated with increases in cardiovascular disease risk. 
However, studies of arsenic’s effects at lower exposure levels are limited and few prospective 
studies exist in the United States using long-term arsenic exposure biomarkers. We conducted a 
prospective analysis of the association between toenail arsenic and cardiovascular disease 
mortality using longitudinal data collected on 3939 participants in the New Hampshire Skin 
Cancer Study. Using Cox proportional hazard models adjusted for potential confounders, we 
estimated hazard ratios and 95% confidence intervals associated with the risk of death from any 
cardiovascular disease, ischemic heart disease, and stroke, in relation to natural-log transformed 
toenail arsenic concentrations. In this US population, although we observed no overall association, 
arsenic exposure measured from toenail clipping samples was related to an increased risk of 
ischemic heart disease mortality among long-term smokers (as reported at baseline), with 
increased hazard ratios among individuals with ≥ 31 total smoking years (HR: 1.52, 95% CI: 1.02, 
2.27), ≥ 30 pack-years (HR: 1.66, 95% CI: 1.12, 2.45), and among current smokers (HR: 1.69, 
95% CI: 1.04, 2.75). These results are consistent with evidence from more highly exposed 
populations suggesting a synergistic relationship between arsenic exposure and smoking on health 
outcomes and support a role for lower-level arsenic exposure in ischemic heart disease mortality.
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Arsenic exposure via contaminated water and diet is a global health issue [1–3]. In the US, 
where over 15 million people rely on private wells as their primary water source, nearly 7% 
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of these systems surpass the maximum contaminant level of 10µg/L for arsenic, a known 
carcinogen [3–5]. Recent studies have suggested that arsenic exposure is not limited 
primarily to those with contaminated drinking water but may be more common, as some 
everyday foods have been identified as potential sources of arsenic exposure, including rice 
and rice products, fruit juices and chicken [6–11].
According to the National Research Council’s recent assessment of arsenic, cardiovascular 
disease (CVD) may be the most important non-cancer disease risk posed by environmental 
arsenic exposures, given the high incidence of cardiovascular disease worldwide [3]. Among 
adults chronically exposed to high levels of arsenic, substantial evidence has supported a 
relationship between arsenic exposure and risk of death from any CVD, particularly 
ischemic heart disease (IHD) [12]. Ecological studies have observed relationships between 
historic arsenic water contamination in Chile and the risk of deaths from acute myocardial 
infarction (historic arsenic level in public water supplies: ~850 µg/L) [13] and more 
recently, increased mortality rates for any CVD, IHD, and stroke in municipalities with 
arsenic concentrations in drinking water > 10µg/L compared to the overall population in 
Spain (mean arsenic level in public water supplies: 2.4 µg/L, range <1 to 118 µg/L) [14]. 
Early epidemiological evidence from Taiwan suggested a dose-response relationship 
between water arsenic exposure and CVD mortality [15]. These findings have been 
supported by prospective studies from Bangladesh using both well water (well arsenic 
median: 62 µg/L, range 0.1–864.0 µg/L) and urinary arsenic measures (urinary arsenic 
median: 199.0 µg/g creatinine, range 6.6–1100 µg/g creatinine) [12,16]. More recent data 
from the Strong Heart Study in the US also indicate that relatively low levels of arsenic 
exposure (urinary arsenic median: 9.7 µg/g creatinine, range 0.1–183.4 µg/g creatinine) may 
increase risk of CVD outcomes [17]. As studies of CVD mortality have primarily focused on 
populations with high levels of chronic arsenic exposure, understanding the relation between 
lower levels of arsenic exposure and CVD mortality requires further investigation. To 
address this issue, we leveraged exposure and health information from a US population-
based study to examine CVD mortality among adults with a range of arsenic exposure, 
including lower levels of exposure that have been largely unexplored.
METHODS
We conducted a prospective analysis of the relation between arsenic exposure and CVD 
mortality using follow-up data collected on participants in the New Hampshire Skin Cancer 
Study, an ongoing population-based study case-control study of keratinocyte cancers, 
described in detail previously [18]. Briefly, cases (n=2881) were 25–74 years old at the time 
of diagnosis and controls (n=1376) were frequency-matched on age and gender. Detailed 
covariate information was collected at baseline by a trained research interviewer during a 
personal interview, usually conducted in-home, and included questions about health history, 
smoking and alcohol use, lifestyle, and sociodemographic information. Data collection 
occurred in three phases, with refinement of the variables collected in each phase. All study 
protocols and materials were approved by the Committee for the Protection of Human 
Subjects of Dartmouth College. All participants provided written informed consent upon 
enrollment.
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Toenail clippings were collected and analyzed from participants upon enrollment, as 
previously described [19,20]. Briefly, toenail samples were washed to remove external 
contamination, freeze-dried, and then stored in sealed vials until they were analyzed for 
arsenic at the University of Missouri Research Reactor Center using standard-comparator 
instrumental neutron activation analysis (NAA). The limit of detection (LOD) for arsenic in 
these samples was 0.01µg/g, with less than 5% of all samples below detection. Samples 
below the LOD were set to one-half the detection limit. Toenail arsenic, an integrated long-
term biomarker of the previous 6–12 months of inorganic arsenic exposure and shown to be 
reliable in our population, served as our primary exposure measure [19–21]. Household 
water samples collected from participants (n=3099 overall participants, n=200 CVD deaths) 
were analyzed in the Dartmouth Trace Element Analysis Core using a Finnigan MAT 
GmbH ELEMENT high resolution inductively coupled mass spectrometer equipped with an 
MY hydride generator (Finnigan MAT GmbH, Bremen, Germany), as previously described 
[20]. The LOD for arsenic in these samples ranged from 0.001 to 0.2µg/L.
We ascertained vital status on study participants through December 31, 2013 by linkage 
with the National Death Index to identify deaths nationwide. Deaths that occurred prior to 
December 31, 2009 were secondarily confirmed with New Hampshire state death 
certificates, as previously described [22]. Analyses of disease-specific mortality were based 
on the primary cause of death as based on the International Classification of Diseases, 10th 
revision (ICD-10). The time interval for our analyses was the time from the reference date 
(diagnosis date of cases and matched date for controls) to either date of death or to 
December 31st, 2013, whichever came first, therefore only right censoring was present in 
this study. We used Cox proportional hazard models to estimate hazard ratios (HR) and 95% 
confidence intervals (CI) associated with the risk of death from any CVD (ICD I00-99), IHD 
(ICD I20-25), and stroke (ICD I60-69), in relation to natural-log (ln) transformed toenail 
arsenic concentrations. In our analyses, we adjusted for potential confounders, including 
educational attainment, BCC status, SCC status, and smoking behavior at baseline (pack-
years). As the majority of participants did not have body mass index (BMI) information 
available (available for 158 of the 312 CVD deaths in our study population), we performed 
restricted analyses to examine the effect of this covariate on our results among those with 
BMI information. Given the growing literature suggesting a potential synergistic role of 
smoking and arsenic exposure in cancer and CVD [12,23,24], we conducted further analyses 
to assess multiplicative interaction between arsenic exposure and smoking status in CVD 
mortality. To obtain p-values for interaction, we added a cross-product term between 
continuous arsenic exposure (ln-transformed toenail arsenic concentrations) and each 
smoking status at baseline (former or current) or a cross-product term between continuous 
arsenic exposure and each continuous smoking variable (pack years, or years of smoking) 
alternatively to the overall model. For ease of interpretation, we estimated the hazard ratios 
associated with one unit increase in continuous arsenic exposure by smoking status at 
baseline (never, former, current), total years of smoking as of reference date (stratified at 31 
years; median among CVD ever smoker cases), and pack-years as of reference date 
(stratified at 30 pack-years; median among CVD ever smoker cases). The hazard ratios were 
estimated with the ‘hazardratio’ statement within the SAS PHREG procedure, allowing the 
calculations in one model without stratifying the data. We used the distribution of smoking 
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behavior among CVD cases to determine median values, as it varied from that of the overall 
population. To account for missing data, we included missing indicator variables. The 
assumption of proportional hazards was examined by testing the cross product terms 
between covariate variables and log function of follow-up time. None of the P values for the 
terms were statistically significant (i.e. p >0.05), nor was a global test of proportionality, 
indicating that the assumption for use of a proportional hazards model was met. Analyses 
were performed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
On average, participants were followed for 14 years (mean: 14.0, SD: 3.8, range 6–20). A 
total of 3,939 individuals contributed 55,034 person-years of observation. A total of 1081 
deaths were observed, of which 312 were classified as CVD deaths. Of these, 154 (49% of 
total CVD deaths) were classified as IHD deaths and 43 (14% of total CVD deaths) as stroke 
deaths. Participants who were men, older, or SCC cases at baseline were more likely to die 
from any CVD (Table 1).
The average toenail arsenic in the overall population (mean (SD): 0.12 (0.14) ppm; median 
(range): 0.09 (0–3.26) ppm) was similar to average levels among those who died from CVD 
(mean (SD): 0.10 (0.08) ppm; median (range): 0.08 (0–0.67) ppm). The average home water 
arsenic level overall (n=3099) was 2.6 µg/L on average (SD: 9.4, median (range): 0.29 (0–
158.1)), with approximately 6% of samples above 10µg/L. Among participants who were 
classified as dying from CVD, about two-thirds (n=200) had provided water samples for 
arsenic assessment. These individuals had home water arsenic levels similar to the overall 
population (mean (SD): 2.3 (7.2) µg/L; median (range): 0.25 (0.01–59.8) µg/L) and 
approximately 7% of samples exceeded the maximum contaminant limit of 10µg/L. Overall, 
we did not detect any significant associations between ln-toenail arsenic concentration and 
the risk of deaths from any CVD, IHD or stroke, after adjustment for age, sex, educational 
attainment, smoking history, or case status (Table 2).
In stratified analyses, we observed associations between ln-toenail arsenic concentration and 
IHD death among those with a longer duration of smoking, higher number of pack-years of 
smoking, and current smokers. In particular, a one unit change in ln-toenail arsenic in 
current smokers was associated with an increased risk of IHD death (HR: 1.69; 95% CI: 
1.04, 2.75, P-interaction = 0.03, Table 3), as compared to individuals who reported never 
smoking (HR: 0.84; 95% CI: 0.58, 1.21) or being a former smoker (HR: 0.82; 95% CI: 0.61, 
1.10). We also found that a one-unit increase in ln-transformed toenail arsenic was related to 
an increased risk of IHD death with a HR of 1.52 (95% CI: 1.02, 2.27) among those who 
smoked for 31 or more years, as compared to those who were never smokers (HR: 0.82, 
95% CI: 0.54, 1.23) or smoked for less than 31 years (HR: 0.79; 95% CI: 0.62, 1.01; P-
interaction = 0.0005, Table 3). Similarly, when we stratified by pack-years of smoking we 
observed increased hazard ratios for IHD death for 30 or more pack-years of smoking (HR: 
1.66; 95% CI: 1.12, 2.45), as compared to never smokers (HR: 0.82, 95% CI: 0.54, 1.23) or 
those with less than 30 pack-years of smoking (HR: 0.77; 95% CI: 0.63, 0.94, P-interaction 
= 0.0009, Table 3). We did not find any clear associations between arsenic exposure on 
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overall CVD or stroke mortality in any stratum of cigarette smokers (i.e., by duration, pack-
years or recency) (data not shown).
In a restricted analysis among those with known BMI (n=158), we did not observe any 
difference in the hazard ratio for cardiovascular disease mortality with additional adjustment 
for this variable, as compared to models that did not include BMI as a covariate among this 
subgroup.
DISCUSSION
We examined CVD mortality in relation to a long-term biomarker of arsenic exposure in a 
US population. Over an average of 14 years of follow-up, we found that higher arsenic 
concentrations were associated with increased IHD mortality among smokers. The data 
support a synergistic effect between cigarette smoking and arsenic exposure on 
cardiovascular mortality [12].
The literature supports the hypothesis that cigarette smoking may increase the risk of 
arsenic-related health outcomes [12,23–25]. Exposure to both arsenic and cigarette smoking 
has been associated with increased risks of bladder and lung cancers [26–29], as well as skin 
lesions [30,31]. Importantly, there is evidence from the HEALS in Bangladesh that among 
arsenic exposed individuals, cigarette smoking may increase risks of CVD morbidity and 
mortality [12,25]. In that large prospective analysis, among individuals with a moderate 
level of well water arsenic exposure (25.3–114.0 µg/L), the joint effect of arsenic exposure 
and cigarette smoking on mortality from heart disease was greater than the sum of their 
individual effects, with approximately 59% of heart disease deaths potentially attributable to 
the interaction between moderate levels of arsenic exposure and smoking [12]. In a more 
recent study of participants in HEALS, lower arsenic methylation capacity appears to 
modify the association between cigarette smoking and risk of both fatal and nonfatal CVD, 
especially heart disease [25]. Despite our smaller sample size and relatively low levels of 
arsenic exposure, similar increases in arsenic-related IHD among long-term smokers were 
observed.
While limited, there are other data that suggest an association between low to moderate 
levels of arsenic exposure and CVD [17,32]. In the Strong Heart Study urinary arsenic levels 
were associated with increased risk of both fatal and nonfatal CVD, coronary heart disease 
and stroke among American Indian men and women [17]. The potential effects of arsenic on 
CVD occurrence is further supported by a growing body of literature indicating that arsenic 
may affect subclinical indicators of CVD, such as carotid intima media thickness and 
elevated blood pressure [32–37]. Additional studies suggest that arsenic impacts endothelial 
function, reactive oxygen signaling and levels of inflammatory mediators [38–41]. Further, 
arsenic has been associated with prolonged QT interval duration, a risk factor for sudden 
cardiac death, in studies from high and lower exposure areas [42,43], including the US-
based Normative Aging Study [44].
Limitations of our study include the quality of cause of death information in death 
certificates, which is prone to misclassification [45–47]. Such errors, however, are unlikely 
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to have been affected by toenail arsenic levels, and thus likely, if anything, led to a bias 
towards the null. However, we cannot rule out the possibility that arsenic exposure and 
smoking behavior may be related to competing causes of death in this population [22]. 
Second, toenail clippings can have limitations as biomarkers due to variability in growth rate 
among individuals, the risk of external contamination, and protocols for collection and 
analysis [48], but we attempted to minimize such issues by collecting toenails immediately 
after bathing, washing them prior to analysis, and using standardized analytical procedures 
for all subjects. Third, arsenic has been previously associated with diabetes, which could be 
a potential mediator of cardiovascular effects [49–51]. However, we lacked information to 
evaluate the extent to which the effects we observe may be related to arsenic’s impact on 
diabetes. Fourth, we only obtained information on smoking behavior upon enrollment into 
the study, thus we were unable to account for changes in smoking status after enrollment, 
which may have biased our results toward the null. Information on secondhand smoke 
exposure was not routinely collected in earlier phases of the study, therefore we were unable 
to include it our analyses. Further, although it is possible that some arsenic measured in 
toenails may be in part contributed by cigarette smoking, previous work has suggested that 
smoking behavior does not significantly impact levels of arsenic in toenails [20]. In this 
population, we examined differences in toenail arsenic levels between ever smokers and 
never smokers, as well as differences in toenail arsenic levels between individuals with 
different lengths of smoking history by pack-years and found that there were no statistically 
significant increases in toenail arsenic associated with ever smoking or pack-years of 
smoking (data not shown).
Lastly, our work was not initially designed for testing the association between arsenic 
exposure and CVD mortality, but to examine the risk factors for keratinocyte cancers. While 
this may somewhat limit the generalizability of our findings, this would not have impacted 
the internal validity of the findings, as this was a prospective analysis and we adjusted for 
case-status.
Taken together with the previous literature, our study suggests that arsenic may be a 
contributing risk factor for IHD in the United States, particularly among long-term smokers. 
Nonetheless, additional studies are needed, particularly to examine low to moderate levels of 
arsenic exposure. Given that arsenic is present in both drinking water and food supplies 
worldwide and that nearly one-third of US deaths are attributable to CVD, even small 
arsenic-related increases in CVD morbidity and mortality in susceptible populations, such as 
long-term smokers, could substantially impact public health.
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Highlights
• Arsenic (As) has been associated with increased cardiovascular disease (CVD) 
risk
• Little is known about CVD effects at lower levels of As exposure common in 
the US
• Few have investigated the joint effects of As and smoking on CVD in US adults
• We examine chronic low-level As exposure and smoking in relation to CVD 
mortality.
• Arsenic exposure may increase ischemic heart disease mortality among smokers 
in US
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Table 1
Baseline characteristics among New Hampshire Skin Cancer Study participants and relation to cardiovascular 
disease mortality, 1993–2013.
Overall participants
N (%)
CVD deaths
N (%)a
Hazard ratio
(95% CI)a
N 3939 312
Age
  Median, years 61 69
  Mean (SD), years 58.5 (11.6) 67.3 (6.5)
  25–59 1829 (46.4) 32 (10.2) 1.0
  60–68 1092 (27.7) 116 (37.2) 3.2 (2.2–4.7)
  69–74 1018 (25.8) 164 (52.6) 4.9 (3.3–7.1)
Gender
  Male 2198 (55.8) 236 (75.6) 1.0
  Female 1741 (44.2) 76 (24.4) 0.5 (0.4–0.7)
Marital Statusb
  Married 3091 (80.6) 243 (79.7) 1.0
  Single, divorced, widowed 744 (19.4) 62 (20.3) 1.2 (0.9–1.6)
Smokingb
  Mean (SD) yearsc 24.9 (14.6) 31.9 (14.4)
  Mean (SD) pack-years 28.1 (27.0) 36.3 (27.4)
  Never 1539 (39.2) 94 (30.3) 1.0
  Former 1774 (45.2) 161 (51.9) 1.0 (0.7–1.3)
  Current 615 (15.7) 55 (17.7) 1.2 (0.9–1.7)
Highest educationb
  Any high school 1463 (37.3) 156 (50.3) 1.0
  Any college 1480 (37.7) 99 (31.9) 0.9 (0.7–1.2)
  Graduate school or higher 982 (25.0) 55 (17.4) 0.7 (0.5–1.0)
Skin cancer statusd
  Control 1376 (34.9) 108 (34.6) 1.0
  BCC 1505 (38.2) 89 (28.5) 0.8 (0.6–1.1)
  SCC 1058 (26.9) 115 (36.9) 1.5 (1.1–1.9)
Abbreviations: 95% CI, 95% confidence interval; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.
a
HR among cardiovascular mortality deaths only, adjusted for educational attainment, marital status, cancer status (case, control), and smoking 
(pack-years).
bSeven cases were missing marital status information, two cases were missing smoking status and two were missing education level.
c
Years smoked prior to reference date.
dCase status in parent New Hampshire Skin Cancer Study.
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Table 2
Hazard ratios for mortality from cardiovascular disease in the NH Skin Cancer Study, per 1 unit increase in ln-
transformed toenail arsenic.
Person-years N* HR (95% CI)**
All cardiovascular disease 55034 312 0.88 (0.76–1.03)
Ischemic heart disease 55034 154 0.94 (0.74–1.19)
Stroke 55034 43 0.90 (0.61–1.33)
*N represents number of deaths.
**
HR among cardiovascular mortality deaths, adjusted for educational attainment, BCC status, SCC status, and smoking (pack-years). Estimates 
were calculated using continuous ln-transformed arsenic.
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Table 3
Hazard ratios for mortality from ischemic heart disease per 1 unit increase in ln-transformed toenail arsenic, 
stratified by smoking behavior.
Person-years N* HR (95% CI)** P-interaction
Smoking status†
  Never 21167 47 0.84 (0.58–1.21)
  Former 25278 80 0.82 (0.61–1.10)
  Current 8589 27 1.69 (1.04–2.75) 0.03
Years of smoking†
  0 years 21202 47 0.82 (0.54–1.23)
  > 0 to < 31 years 20877 50 0.79 (0.62–1.01)
  ≥ 31 years 11420 53 1.52 (1.02–2.27) 0.0005‡
Pack-years of smoking†
  0 years 21202 47 0.82 (0.54–1.23)
  > 0 to < 30 pack-years 20697 49 0.77 (0.63–0.94)
  ≥ 30 pack-years 11600 54 1.66 (1.12–2.45) 0.0009‡
*N represents number of deaths.
**
HR among ischemic heart disease mortality deaths only, adjusted for educational attainment, BCC status, and SCC status.
†
HRs were calculated from a single model with continuous ln-transformed arsenic and categorical smoking status.
‡
P-values for interaction were estimated from models that included cross-product terms for continuous toenail arsenic and continuous smoking 
years (or pack-years).
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